zoldonrasib
AXP000029.1 · Targeted small molecule
- Platform
- small molecule
- Targets
- KRAS
- Originator
- Revolution Medicines
- Sponsor
- Revolution Medicines
Names
Cross-references
- NCI Thesaurus
- C201828
- Wikidata
- Q131410989
- FDA UNII
- XJ52BWK3XE
Approvals
No regulatory approval recorded.
Clinical trials (8)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT07805954 | Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma | Recruiting | Phase 3 | 2026-08-28 | 2029-03 | 400 | PDAC; PDAC - Pancreatic Ductal Adenocarcinoma; Pancreatic Adenocarcinoma; Pancreatic Adenocarcinoma Metastatic; Pancreatic Adenosquamous Carcinoma; Pancreatic Cancer; Pancreatic Cancer Metastatic; Pancreatic Ductal Adenocarcinoma (PDAC) |
| NCT07777822 | Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLC | Recruiting | Phase 3 | 2026-08-14 | 2029-10 | 430 | Lung Cancer (NSCLC); Metastatic NSCLC - Non-Small Cell Lung Cancer; Metastatic Non-Squamous Non-Small Cell Lung Cancer; NSCLC; Non-Small Cell Lung Cancer NSCLC; Non-Squamous Non Small Cell Lung Cancer; Non-small Cell Lung Cancer |
| NCT07621718 | Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 ) | Recruiting | Phase 3 | 2026-05-22 | 2028-12-30 | 670 | PDAC; PDAC - Pancreatic Ductal Adenocarcinoma; Pancreatic Adenocarcinoma; Pancreatic Adenocarcinoma Metastatic; Pancreatic Adenosquamous Carcinoma; Pancreatic Cancer; Pancreatic Cancer Metastatic; Pancreatic Ductal Adenocarcinoma (PDAC) |
| NCT07397338 | Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors | Recruiting | Phase 1/2 | 2026-01-30 | 2029-05 | 370 | Advanced Solid Tumors; CRC; Colorectal Cancer (CRC); Metastatic Solid Tumors; NSCLC; Non-small Cell Lung Cancer (NSCLC) |
| NCT06922591 | Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients | Recruiting | Phase 1/2 | 2025-05-31 | 2027-06 | 183 | Lung Cancer; MTAP Deletion; NSCLC; PDAC; PDAC - Pancreatic Ductal Adenocarcinoma; Pancreatic Cancer Metastatic; RAS Mutation; Thoracic Cancer |
| NCT06445062 | Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors | Recruiting | Phase 1/2 | 2024-05-24 | 2028-09-30 | 1130 | CRC; Colorectal Cancer; Gastrointestinal Cancer; Metastatic Pancreatic Ductal Adenocarcinoma; PDAC; Pancreatic Ductal Adenocarcinoma |
| NCT06162221 | Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC | Recruiting | Phase 1/2 | 2024-01-18 | 2027-06 | 616 | KRAS G12C-mutated Solid Tumors, Lung Cancer; KRAS, NRAS, HRAS-mutated NSCLC; Lung Cancer Stage IV, Advanced Solid Tumor, Cancer; Non-Small Cell Lung Cancer, NSCLC; RAS G12D-mutated NSCLC |
| NCT06040541 | Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors | Recruiting | Phase 1 | 2023-09-07 | 2026-12-31 | 604 | Advanced Solid Tumors; Colorectal Cancer (CRC); Non-small Cell Lung Cancer (NSCLC); Pancreatic Ductal Adenocarcinoma (PDAC) |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 42581230 | Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancer. | Nature medicine | 2026 | name in abstract: zoldonrasib |
| PMID 40056080 | Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers. | Journal of medicinal chemistry | 2025 | cited by trial NCT06040541 |
| PMID 40705880 | A neomorphic protein interface catalyzes covalent inhibition of RASG12D aspartic acid in tumors. | Science (New York, N.Y.) | 2025 | cited by trial NCT06040541 |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 42436354 | CDK8 remodels the tumor microenvironment and promotes resistance to KRASG12D inhibitors and daraxonrasib in PDAC. | The EMBO journal | 2026 | name in abstract: zoldonrasib |
| PMID 42612796 | Therapeutic targeting of RAS-mediated resistance in oncogene-driven lung cancer. | Annals of oncology : official journal of the European Society for Medical Oncology | 2026 | name in abstract: zoldonrasib |
| PMID 42615854 | Progress and challenges in the design and development of selective KRAS G12D-targeted drug discovery: inhibitors, degraders and emerging therapeutic strategies. | Future medicinal chemistry | 2026 | name in abstract: RMC-9805 |
| PMID 42645357 | Targeted Therapy in Pancreatic Ductal Adenocarcinoma: Current Advances and Challenges. | Current oncology (Toronto, Ont.) | 2026 | name in abstract: zoldonrasib |
| PMID 42663603 | The ongoing first-line treatment race for metastatic pancreatic ductal adenocarcinomas: will a tough disease lose its horror? | Future oncology (London, England) | 2026 | name in abstract: zoldonrasib |
| PMID 42667948 | XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant pancreatic ductal adenocarcinoma. | Cancer letters | 2026 | name in abstract: zoldonrasib |
| PMID 42678463 | Emerging Therapeutic Strategies for Non-G12C KRAS Mutations in Colorectal Cancer: Focusing on G12D and G12V. | Journal of gastrointestinal cancer | 2026 | name in abstract: zoldonrasib |
| PMID 42720810 | Beyond KRASG12C: emerging therapeutic strategies, patent landscape, and clinical progress in targeting KRAS-mutant cancers. | Medical oncology (Northwood, London, England) | 2026 | name in abstract: RMC-9805 |
| PMID 42759542 | Targeting KRAS-Mutant Lung Cancers. | Journal of the National Comprehensive Cancer Network : JNCCN | 2026 | name in abstract: zoldonrasib |
| PMID 42870846 | Activity and specificity of KRAS variants-directed Revolution Medicines Company (RMC) compounds for pleural effusion-derived non-small cell lung cancer cell lines. | Translational lung cancer research | 2026 | name in abstract: zoldonrasib |
| PMID 42963543 | KRAS in pancreatic cancer: from molecular biology to transformative therapeutics. | Journal of hematology & oncology | 2026 | name in abstract: zoldonrasib |
| PMID 42971499 | Saturation mutagenesis library screening identifies on-target secondary resistance mutations in KRASG12D-selective inhibitors. | Cancer letters | 2026 | name in abstract: RMC-9805 |
| PMID 42988458 | Simultaneous LC-MS/MS quantification of four KRAS inhibitors (RMC-6236, RMC-9805, RMC-7977, and MRTX1133) in human plasma: toward therapeutic drug monitoring in pancreatic ductal adenocarcinoma. | Bioanalysis | 2026 | name in title: RMC-9805 |
| PMID 40624835 | Drugging the 'undruggable' KRAS: breakthroughs, challenges, and opportunities in pancreatic cancer. | Cancer biology & medicine | 2025 | name in abstract: RMC-9805 |
| PMID 40805153 | Treatment of KRAS-Mutated Pancreatic Cancer: New Hope for the Patients? | Cancers | 2025 | name in abstract: RMC-9805 |
| PMID 41423807 | Targeting KRAS G12D: Advances in Inhibitor Design. | Thoracic cancer | 2025 | name in abstract: RMC-9805 |
NIH grants
| Project | Title | Organisation | PI | Years | Linked by |
|---|---|---|---|---|---|
| R03CA304041 | Targeting the HER Family in KRAS Mutant Colorectal Cancer | UNIVERSITY OF CINCINNATI | GARRETT, JOAN T. | 2025–2025 | name in abstract: RMC-9805 |
Notes
KRAS G12D(ON) covalent tri-complex inhibitor. NCIt also lists RM-036 (unverified elsewhere).
How to cite
zoldonrasib (AXP000029.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000029.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.